Small Intestine Bacterial Overgrowth
3
1
1
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Trimethoprimsulfamethoxazole Tmpsmx
Research Leaders
17 sponsors active, led by Virginia Commonwealth University
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children
Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension
Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings
Research Network
Common Treatments
- Trimethoprimsulfamethoxazole Tmpsmx1
- Metronidazole1
- Amoxicillinclavulanate 41 Formulation1
- Rifaximin1
Active Sponsors
- Virginia Commonwealth University2
- International Centre for Diarrhoeal Disease Research, Bangladesh2
- University of Virginia2
- Air Force Military Medical University, China1
- Beijing Friendship Hospital1
Top Investigators
University of Virginia
Peking Union Medical College Hospital
University of Virginia
International Centre for Diarrhoeal Disease Research, Bangladesh